Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
DISHMAN PHARMA | ASTRAZENECA PHARMA | DISHMAN PHARMA/ ASTRAZENECA PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 97.8 | 25.7% | View Chart |
P/BV | x | 3.3 | 27.3 | 12.3% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
ASTRAZENECA PHARMA Mar-14 |
DISHMAN PHARMA/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 1,285 | 29.1% | |
Low | Rs | 129 | 634 | 20.3% | |
Sales per share (Unadj.) | Rs | 197.8 | 189.6 | 104.3% | |
Earnings per share (Unadj.) | Rs | 21.2 | -0.2 | -10,415.4% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 3.8 | 903.2% | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 179.9 | 68.6 | 262.1% | |
Shares outstanding (eoy) | m | 80.69 | 25.00 | 322.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 5.1 | 25.1% | |
Avg P/E ratio | x | 11.9 | -4,712.7 | -0.3% | |
P/CF ratio (eoy) | x | 7.2 | 249.6 | 2.9% | |
Price / Book Value ratio | x | 1.4 | 14.0 | 10.0% | |
Dividend payout | % | 9.4 | 0 | - | |
Avg Mkt Cap | Rs m | 20,306 | 23,988 | 84.7% | |
No. of employees | `000 | 0.8 | 1.6 | 53.2% | |
Total wages/salary | Rs m | 5,355 | 1,605 | 333.7% | |
Avg. sales/employee | Rs Th | 19,252.7 | 3,040.2 | 633.3% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,029.2 | 627.6% | |
Avg. net profit/employee | Rs Th | 2,064.1 | -3.3 | -63,219.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 4,740 | 336.7% | |
Other income | Rs m | 265 | 92 | 288.2% | |
Total revenues | Rs m | 16,226 | 4,832 | 335.8% | |
Gross profit | Rs m | 4,103 | -130 | -3,161.2% | |
Depreciation | Rs m | 1,091 | 101 | 1,077.7% | |
Interest | Rs m | 944 | 0 | - | |
Profit before tax | Rs m | 2,334 | -139 | -1,680.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 139 | 0.0% | |
Tax | Rs m | 624 | 5 | 12,251.5% | |
Profit after tax | Rs m | 1,711 | -5 | -33,616.9% | |
Gross profit margin | % | 25.7 | -2.7 | -938.8% | |
Effective tax rate | % | 26.7 | -3.7 | -729.2% | |
Net profit margin | % | 10.7 | -0.1 | -9,983.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 2,726 | 404.1% | |
Current liabilities | Rs m | 9,517 | 2,435 | 390.8% | |
Net working cap to sales | % | 9.4 | 6.1 | 153.0% | |
Current ratio | x | 1.2 | 1.1 | 103.4% | |
Inventory Days | Days | 110 | 74 | 149.8% | |
Debtors Days | Days | 35 | 41 | 85.5% | |
Net fixed assets | Rs m | 16,304 | 1,035 | 1,574.8% | |
Share capital | Rs m | 161 | 50 | 322.8% | |
"Free" reserves | Rs m | 12,907 | 942 | 1,369.6% | |
Net worth | Rs m | 14,516 | 1,716 | 845.9% | |
Long term debt | Rs m | 4,189 | 0 | - | |
Total assets | Rs m | 29,805 | 4,156 | 717.2% | |
Interest coverage | x | 3.5 | NM | - | |
Debt to equity ratio | x | 0.3 | 0 | - | |
Sales to assets ratio | x | 0.5 | 1.1 | 47.0% | |
Return on assets | % | 8.9 | -0.1 | -7,274.7% | |
Return on equity | % | 11.8 | -0.3 | -3,974.1% | |
Return on capital | % | 17.5 | 0 | - | |
Exports to sales | % | 24.8 | 5.7 | 434.8% | |
Imports to sales | % | 3.7 | 6.5 | 57.8% | |
Exports (fob) | Rs m | 3,956 | 270 | 1,464.2% | |
Imports (cif) | Rs m | 596 | 306 | 194.7% | |
Fx inflow | Rs m | 4,952 | 375 | 1,321.8% | |
Fx outflow | Rs m | 697 | 470 | 148.2% | |
Net fx | Rs m | 4,255 | -96 | -4,452.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | -8 | -34,400.0% | |
From Investments | Rs m | -1,529 | -146 | 1,049.3% | |
From Financial Activity | Rs m | -941 | 862 | -109.2% | |
Net Cashflow | Rs m | 316 | 709 | 44.7% |
Indian Promoters | % | 61.4 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 75.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 0.3 | 1,233.3% | |
FIIs | % | 12.7 | 15.7 | 80.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 9.1 | 242.9% | |
Shareholders | 46,261 | 12,856 | 359.8% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: FULFORD INDIA VENUS REMEDIES STERLING BIOTECH WOCKHARDT LTD. SUVEN LIFE
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
| |
Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.
For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsThe real estate sector is ready to make a comeback. This is the stock to consider buying.
During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.
Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More
| |